Bio

Bio


Dr. Goodyear is committed to providing excellent clinical care to patients and conducting research to advance our understanding of how to treat and live well with MS. She has served as a Principal Investigator on multiple MS studies, and is committed to providing the opportunity for all MS patients to participate in research, including CIS, RRMS, SPMS and PPMS.

Other research interests include neuromyelitis optica, cost effectiveness and epidemiological research. Dr. Goodyear was awarded the Sylvia Lawry Clinical Trials Fellowship by the MS Society and completed a Masters in Epidemiology during her training. Dr. Goodyear completed her Neurology Residency at Stanford University Medical Center and served as Chief Resident. Dr. Goodyear attended Brown University for her undergraduate studies and began her medical career with two years of public health work in Senegal, West Africa as a Peace Corps Volunteer.

Clinical Focus


  • Multiple Sclerosis
  • Neuromyelitis Optica
  • Transverse Myelitis
  • Multiple Sclerosis, Relapsing-Remitting
  • Multiple Sclerosis, Chronic Progressive
  • Optic Neuritis
  • Neurology

Academic Appointments


Administrative Appointments


  • Medical Director, Stanford Neurosciences Clinical Trials Group (2013 - Present)

Honors & Awards


  • Chief Resident in Neurology, Stanford University School of Medicine, Department of Neurology (2010-2011)
  • SPARK Translational Science Research Grant, SPARK, Stanford School of Medicine (2013-2015)
  • Sylvia Lawry Physician Fellow in Clinical Trials, National Multiple Sclerosis Society (08/2011-08/2013)

Professional Education


  • Medical Education:Tufts University (2007) MA
  • Fellowship:Stanford University School of Medicine (2013) CA
  • Board Certification: Neurology, American Board of Psychiatry and Neurology (2011)
  • Residency:Stanford University School of Medicine (2011) CA
  • Internship:Stanford University School of Medicine (2008) CA
  • MS Epidemiology, Stanford University School of Medicine, Department of Health Research and Policy, Epidemiology and Biostatistics (2013)
  • Resident in Neurology, Stanford University School of Medicine, Department of Neurology, Neurology (2011)
  • Internship in internal medicine, Stanford University School of Medicine, Internal Medicine (2008)

Research & Scholarship

Clinical Trials


  • Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Recruiting

    Neuromyelitis Optica (NMO) is a rare, devastating demyelinating disease of the central nervous system (CNS) that has different causes and treatments from the more common demyelinating disease multiple sclerosis (MS). Current NMO therapies are nonspecific and have varying and often suboptimal benefit. The investigators will evaluate whether use of alpha1-antitrypsin (A1AT, an FDA-approved medication for patients with congenital deficiency of A1AT associated with emphysema) can benefit acute attacks of NMO, improving patient disability and quality of life.

    View full details

  • Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex Recruiting

    The primary objective of the study is to evaluate the efficacy of BIIB033 in subjects with active relapsing MS when used concurrently with Avonex. Secondary objectives of this study in this study population are to assess the safety, tolerability, and population PK of BIIB033 when used concurrently with Avonex

    View full details

  • Vitamin D Supplementation in Multiple Sclerosis Recruiting

    Low vitamin D levels have been shown to increase a person's risk of developing multiple sclerosis (MS), and patients with MS who have lower vitamin D levels are at increased risk of having attacks. However, it is not known if giving supplemental vitamin D to those with MS reduces the risk of attacks, and some research suggests that vitamin D could even be harmful to people with MS. In this clinical trial, patients with relapsing-remitting MS will receive high-dose or low-dose oral vitamin D in addition to an approved therapy for MS, glatiramer acetate. Patients will be evaluated for two years, and the effect of high-dose vitamin D supplementation on the rate of MS attacks and on the number of new lesions and change in brain volume on MRI will be determined. Establishing this association will have major implications for the treatment of individuals with MS throughout the world.

    View full details

  • An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Recruiting

    This is a Phase I, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study designed to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of single intravenous (IV) administrations of rHIgM22 in patients with all clinical presentations of MS.

    View full details

Publications

Journal Articles


  • Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein MULTIPLE SCLEROSIS JOURNAL Herges, K., de Jong, B. A., Kolkowitz, I., Dunn, C., Mandelbaum, G., Ko, R. M., Maini, A., Han, M. H., Killestein, J., Polman, C., Goodyear, A. L., Dunn, J., Steinman, L., Axtell, R. C. 2012; 18 (4): 398-408

    Abstract

    The pathology of neuromyelitis optica (NMO), in contrast to multiple sclerosis, comprises granulocyte infiltrates along extensive lengths of spinal cord, as well as optic nerve. Furthermore, IFN-? treatment worsens NMO. We recently found that experimental autoimmune encephalomyelitis (EAE) induced with Th17 cells is exacerbated by IFN-?, in contrast to disease induced with Th1 where treatment attenuated symptoms.This study demonstrates the similarities between NMO and Th17 EAE and how neutrophils mediate pathology in Th17 disease.Levels of blood biomarkers in NMO were assessed by Luminex and ELISA. Effects of IFN-? on neutrophils were assessed by culture assays and immunofluorescence. EAE was induced by transfer of myelin-specific Th1 or Th17 cells and treated with Sivelestat sodium hydrate, a neutrophil elastase inhibitor.We show Th17 cytokines, granulocyte chemokines, type 1 interferon and neutrophil elastase are elevated in patients with definitive NMO. In culture, we find that IFN-? stimulates neutrophils to release neutrophil elastase. In Th17 EAE, we demonstrate neutrophilic infiltration in the optic nerve and spinal cord which was not present in Th1 EAE. Blockade of neutrophil elastase with Sivelestat had efficacy in Th17 EAE but not Th1 EAE.The similarities between Th17 EAE and NMO indicate that this model represents several aspects of NMO. Neutrophils are critical in the pathologies of both Th17-EAE and NMO, and therefore blockade of neutrophil elastase is a promising target in treating NMO.

    View details for DOI 10.1177/1352458512440060

    View details for Web of Science ID 000302289900006

    View details for PubMedID 22343184

Conference Proceedings


  • A New Cost-effectiveness Microsimulation Model for Glatiramer Acetate and Dimethyl Fumarate. ECTRIMS Leeper, A., Owens, D., Goldhaber-Friebert , J., Goodyear, A. 2013

Stanford Medicine Resources: